CPS, which assesses PD-L1 expression in both tumor and immune cells, has firmly established itself as a biomarker for predicting ICIs response, whereas distribution of CPS in HPV(+)OPSCC has not been comprehensively studied. The gene discussed is CD274; the disease is neoplasm.